Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Angiotensin-receptor blockers (ARBs) are increasingly prescribed due to superior tolerability compared to angiotensin-converting enzyme inhibitors.
• Significant variations exist in ARB pharmacological profiles, leading to differing clinical efficacies.
• Patient management decisions regarding ARB selection require an evidence-based approach tailored to individual needs.

Purpose of the Study:

• To provide evidence-based guidance on selecting the appropriate ARB based on patient risk stratification.
• To highlight the specific benefits of telmisartan in high-risk cardiovascular patient populations.

Main Methods:

• Review of pharmacological profiles and clinical trial data for various ARBs.
• Analysis of the Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial (ONTARGET) results.
• Stratification of patient risk factors, including hypertension and heart failure.

Main Results:

• For low-risk hypertension, ARBs with sustained 24-hour blood pressure reduction are suitable.
• For very high-risk patients (e.g., heart failure), ARBs with demonstrated efficacy in this group are preferred.
• Telmisartan demonstrated equivalent cardiovascular protection to ACE inhibitors in high-risk patients with a better side-effect profile, as shown in the ONTARGET trial.

Conclusions:

• ARB selection should be individualized based on patient risk and specific pharmacological properties.
• Telmisartan emerges as a preferred ARB for increased-risk patients due to its established safety and efficacy.
• Evidence-based selection of ARBs optimizes patient outcomes in cardiovascular management.